uric acid has been researched along with Diabetes Insipidus in 25 studies
Uric Acid: An oxidation product, via XANTHINE OXIDASE, of oxypurines such as XANTHINE and HYPOXANTHINE. It is the final oxidation product of purine catabolism in humans and primates, whereas in most other mammals URATE OXIDASE further oxidizes it to ALLANTOIN.
uric acid : An oxopurine that is the final oxidation product of purine metabolism.
6-hydroxy-1H-purine-2,8(7H,9H)-dione : A tautomer of uric acid having oxo groups at C-2 and C-8 and a hydroxy group at C-6.
7,9-dihydro-1H-purine-2,6,8(3H)-trione : An oxopurine in which the purine ring is substituted by oxo groups at positions 2, 6, and 8.
Diabetes Insipidus: A disease that is characterized by frequent urination, excretion of large amounts of dilute URINE, and excessive THIRST. Etiologies of diabetes insipidus include deficiency of antidiuretic hormone (also known as ADH or VASOPRESSIN) secreted by the NEUROHYPOPHYSIS, impaired KIDNEY response to ADH, and impaired hypothalamic regulation of thirst.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Objective To investigate the level of serum uric acid in patients with diabetes insipidus (DI),summarize the clinical characteristics of central diabetes insipidus (CDI) patients with hyperuricemia (HUA),and analyze the factors affecting the level of serum uric acid in the patients with CDI." | 8.31 | [Serum Uric Acid Level and Its Influencing Factors in Patients with Diabetes Insipidus]. ( Chi, Y; Duan, L; Ping, F; Wang, SH; Wang, X; Yuan, T; Zhu, HJ, 2023) |
| "In hyponatremia related to syndrome of inappropriate antidiuretic hormone (SIADH), hypouricemia is explained primarily by the high uric acid clearance rate that results from the decrease in tubular uric acid reabsorption." | 7.69 | Evidence in hyponatremia related to inappropriate secretion of ADH that V1 receptor stimulation contributes to the increase in renal uric acid clearance. ( Decaux, G; Gulbis, B; Namias, B; Soupart, A, 1996) |
| "Purine inborn errors of metabolism (IEM) are serious hereditary disorders, which should be suspected in any case of neonatal fitting, failure to thrive, recurrent infections, neurological deficit, renal disease, self-mutilation and other manifestations." | 6.44 | Uric acid changes in urine and plasma: an effective tool in screening for purine inborn errors of metabolism and other pathological conditions. ( Aquino Neto, FR; de Oliveira, ML; Gomes, LN; Oliveira, CP; Scalco, FB; Simoni, RE, 2007) |
| "Objective To investigate the level of serum uric acid in patients with diabetes insipidus (DI),summarize the clinical characteristics of central diabetes insipidus (CDI) patients with hyperuricemia (HUA),and analyze the factors affecting the level of serum uric acid in the patients with CDI." | 4.31 | [Serum Uric Acid Level and Its Influencing Factors in Patients with Diabetes Insipidus]. ( Chi, Y; Duan, L; Ping, F; Wang, SH; Wang, X; Yuan, T; Zhu, HJ, 2023) |
| "In hyponatremia related to syndrome of inappropriate antidiuretic hormone (SIADH), hypouricemia is explained primarily by the high uric acid clearance rate that results from the decrease in tubular uric acid reabsorption." | 3.69 | Evidence in hyponatremia related to inappropriate secretion of ADH that V1 receptor stimulation contributes to the increase in renal uric acid clearance. ( Decaux, G; Gulbis, B; Namias, B; Soupart, A, 1996) |
| "Purine inborn errors of metabolism (IEM) are serious hereditary disorders, which should be suspected in any case of neonatal fitting, failure to thrive, recurrent infections, neurological deficit, renal disease, self-mutilation and other manifestations." | 2.44 | Uric acid changes in urine and plasma: an effective tool in screening for purine inborn errors of metabolism and other pathological conditions. ( Aquino Neto, FR; de Oliveira, ML; Gomes, LN; Oliveira, CP; Scalco, FB; Simoni, RE, 2007) |
| "Uric acid level was high in the serum and the carbamide-N and creatinine showed also increased values." | 1.28 | [Hyperuricacidemic nephrogenic diabetes insipidus]. ( Lengyel, I, 1991) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 18 (72.00) | 18.7374 |
| 1990's | 4 (16.00) | 18.2507 |
| 2000's | 2 (8.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (4.00) | 2.80 |
| Authors | Studies |
|---|---|
| Wang, SH | 1 |
| Zhu, HJ | 1 |
| Duan, L | 1 |
| Ping, F | 1 |
| Wang, X | 1 |
| Chi, Y | 1 |
| Yuan, T | 1 |
| SHEARN, MA | 1 |
| TU, WH | 1 |
| Simoni, RE | 1 |
| Gomes, LN | 1 |
| Scalco, FB | 1 |
| Oliveira, CP | 1 |
| Aquino Neto, FR | 1 |
| de Oliveira, ML | 1 |
| Murphy, HM | 1 |
| Wideman, CH | 1 |
| Decaux, G | 2 |
| Namias, B | 2 |
| Gulbis, B | 1 |
| Soupart, A | 2 |
| Prospert, F | 1 |
| Sheikh-Hamad, D | 1 |
| Ayus, CJ | 1 |
| Kelly, SJ | 1 |
| Delnomdedieu, M | 1 |
| Oliverio, MI | 1 |
| Williams, LD | 1 |
| Saifer, MGP | 1 |
| Sherman, MR | 1 |
| Coffman, TM | 1 |
| Johnson, GA | 1 |
| Hershfield, MS | 1 |
| Conger, JD | 1 |
| Falk, SA | 1 |
| Savi, M | 1 |
| Suki, WN | 2 |
| Krízek, V | 1 |
| Kuszyk, T | 1 |
| Wojnarowski, M | 1 |
| Lengyel, I | 1 |
| Harper, M | 1 |
| Hatjis, CG | 1 |
| Appel, RG | 1 |
| Austin, WE | 1 |
| Thurau, K | 1 |
| Valtin, H | 1 |
| Schnermann, J | 1 |
| Holmes, EW | 1 |
| Kelley, WN | 1 |
| Wyngaarden, JB | 1 |
| Martinez-Maldonado, M | 1 |
| Eknoyan, G | 1 |
| Steele, TH | 1 |
| Underwood, JL | 1 |
| Dudgeon, KL | 1 |
| Anderton, JL | 1 |
| Kincaid-Smith, P | 1 |
| Gorden, P | 1 |
| Robertson, GL | 1 |
| Seegmiller, JE | 1 |
| Lant, AF | 1 |
| Wilson, GM | 1 |
| Zucchelli, P | 1 |
| Petrella, A | 1 |
| Fusaroli, M | 1 |
| Sasdelli, M | 1 |
| Melica, A | 1 |
| Nash, HL | 1 |
| Fitz, AE | 1 |
| Wilson, WR | 1 |
| Kirkendall, WM | 1 |
| Kioschos, JM | 1 |
| Brown, DM | 1 |
| Reynolds, JW | 1 |
| Michael, AF | 1 |
| Ulstrom, RA | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Phase II Multidose Study of Intravenous PEG-uricase in Patients With Refractory Gout[NCT00111657] | Phase 2 | 30 participants (Actual) | Interventional | 2004-12-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Number of patients who developed antibodies to PEG-uricase (NCT00111657)
Timeframe: baseline, then prior to infusions and 7 wks after last infusion
| Intervention | participants (Number) |
|---|---|
| Pegloticase | 15 |
The highest drug concentration in the blood after the first infusion of study drug. (NCT00111657)
Timeframe: 2 hours
| Intervention | mU/mL (Mean) |
|---|---|
| Single Arm - Pegloticase | 25.6 |
The lowest drug concentration in the blood after the first infusion of study drug. (NCT00111657)
Timeframe: 21 days after the infusion
| Intervention | mU/mL (Mean) |
|---|---|
| Single Arm - Pegloticase | 4.9 |
(NCT00111657)
Timeframe: Baseline to Day 105
| Intervention | Participants (Number) |
|---|---|
| Single Arm | 17 |
Count of tenderness and swelling of 68 joints (NCT00111657)
Timeframe: Basline and day 134
| Intervention | joints (Median) | |||
|---|---|---|---|---|
| Number of Tender joints at baseline | Number of Tender joints at day 134 | Number of Swollen jonts at baseline | Number of Swollen jonts at day 134 | |
| Pegloticase | 13 | 2 | 9 | 6 |
8 reviews available for uric acid and Diabetes Insipidus
| Article | Year |
|---|---|
Uric acid changes in urine and plasma: an effective tool in screening for purine inborn errors of metabolism and other pathological conditions.
Topics: Biomarkers; Diabetes Insipidus; Female; Humans; Kidney Diseases; Metabolism, Inborn Errors; Polycyst | 2007 |
[Genetic bases of metabolic tubular nephropathies].
Topics: Acidosis, Renal Tubular; Amino Acids; Bartter Syndrome; Cystinuria; Diabetes Insipidus; Fanconi Synd | 1979 |
Renal involvement in leukemia and lymphoma.
Topics: Amyloidosis; Blood Vessels; Diabetes Insipidus; Humans; Hypercalcemia; Hyponatremia; Kidney; Kidney | 1976 |
[Inborn errors of metabolism and their significance in urology and nephrology].
Topics: Acidosis, Renal Tubular; Alkaptonuria; Cystinuria; Diabetes Insipidus; Female; Glycine; Gout; Humans | 1976 |
Kidney.
Topics: Acid-Base Equilibrium; Aldosterone; Amino Acids; Angiotensin II; Animals; Diabetes Insipidus; Glomer | 1968 |
Editorial: The kidney and uric acid excretion in man.
Topics: Angiotensin II; Animals; Biological Transport, Active; Blood Proteins; Diabetes Insipidus; Diet, Sod | 1972 |
Diuretics in nonedematous states. Physiological basis for the clinical use.
Topics: Acidosis, Renal Tubular; Barbiturates; Calcium; Chlorothiazide; Cystinuria; Diabetes Insipidus; Diab | 1973 |
Diuretics. II. Clinical considerations.
Topics: Administration, Oral; Aminophylline; Ascites; Calcium; Carbohydrate Metabolism; Carbonic Anhydrase I | 1971 |
1 trial available for uric acid and Diabetes Insipidus
| Article | Year |
|---|---|
Long-term therapy of diabetes insipidus with oral benzothiadiazine and phthalimidine diuretics.
Topics: Administration, Oral; Adult; Antihypertensive Agents; Benzothiadiazines; Blood Glucose; Child; Diabe | 1971 |
16 other studies available for uric acid and Diabetes Insipidus
| Article | Year |
|---|---|
[Serum Uric Acid Level and Its Influencing Factors in Patients with Diabetes Insipidus].
Topics: Adolescent; Adult; Child; Cholesterol; Creatinine; Diabetes Insipidus; Diabetes Mellitus; Humans; Hy | 2023 |
NEPHROGENIC DIABETIC INSIPIDUS AND OTHER DEFECTS OF RENAL TUBULAR FUNCTION IN SJOERGREN'S SYNDROME.
Topics: Acidosis; Acidosis, Renal Tubular; Ammonium Chloride; Diabetes Insipidus; Diabetes Mellitus; Humans; | 1965 |
Basic alterations in serum levels of several chemical substances in Brattleboro rats.
Topics: Aging; Alkaline Phosphatase; Animals; Blood Glucose; Blood Proteins; Creatinine; Diabetes Insipidus; | 1982 |
Evidence in hyponatremia related to inappropriate secretion of ADH that V1 receptor stimulation contributes to the increase in renal uric acid clearance.
Topics: Adult; Body Water; Deamino Arginine Vasopressin; Diabetes Insipidus; Humans; Hyponatremia; Inappropr | 1996 |
Hyperuricemia as a clue for central diabetes insipidus (lack of V1 effect) in the differential diagnosis of polydipsia.
Topics: Adult; Antihypertensive Agents; Deamino Arginine Vasopressin; Diabetes Insipidus; Diabetes Insipidus | 1997 |
Antidiuretic hormone and renal clearance of uric acid.
Topics: Diabetes Insipidus; Diagnosis, Differential; Humans; Inappropriate ADH Syndrome; Natriuresis; Osmola | 1998 |
Diabetes insipidus in uricase-deficient mice: a model for evaluating therapy with poly(ethylene glycol)-modified uricase.
Topics: Animals; Body Water; Diabetes Insipidus; Disease Models, Animal; Gout; Humans; Kidney Concentrating | 2001 |
Intrarenal dynamics in the pathogenesis and prevention of acute urate nephropathy.
Topics: Animals; Blood Pressure; Diabetes Insipidus; Diuresis; Glomerular Filtration Rate; Hydrogen-Ion Conc | 1977 |
[Renal diabetes insipidus with hyperuricemia in an infant].
Topics: Age Factors; Diabetes Insipidus; Female; Humans; Infant; Kidney Diseases; Uric Acid | 1976 |
[Hyperuricacidemic nephrogenic diabetes insipidus].
Topics: Diabetes Insipidus; Drinking; Humans; Male; Middle Aged; Nephritis; Polyuria; Thirst; Uric Acid | 1991 |
Vasopressin-resistant diabetes insipidus, liver dysfunction, hyperuricemia and decreased renal function. A case report.
Topics: Adult; Diabetes Insipidus; Female; Hepatitis; Humans; Kidney Diseases; Pregnancy; Pregnancy Complica | 1987 |
Urate excretion and urine flow in a lithium-induced diabetes insipidus rat model.
Topics: Animals; Diabetes Insipidus; Disease Models, Animal; Injections, Intraperitoneal; Lithium; Male; Rat | 1974 |
Hyperuricemia, a concomitant of congenital vasopressin-resistant diabetes insipidus in the adult.
Topics: Adult; Aminohippuric Acids; Arginine; Child; Child, Preschool; Creatinine; Diabetes Insipidus; Diet; | 1971 |
[Ethacrynic acid: research on the mechanism of action and clinical use].
Topics: Adolescent; Adult; Aged; Child; Diabetes Insipidus; Diuresis; Edema; Ethacrynic Acid; Female; Heart | 1968 |
Cardiorenal hemodynamic effects of ethacrynic acid.
Topics: Chlorothiazide; Diabetes Insipidus; Edema; Electrolytes; Ethacrynic Acid; Heart; Heart Failure; Hear | 1966 |
The use and mode of action of ethacrynic acid in nephrogenic diabetes insipidus.
Topics: Blood Chemical Analysis; Child; Child, Preschool; Chlorothiazide; Diabetes Insipidus; Diuresis; Etha | 1966 |